The CAR-T Revolution: Side Effects, Results & What's Next | Tara Gregory, MD

The CAR-T Revolution: Side Effects, Results & What's Next | Tara Gregory, MD
Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026
ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026
Bispecific Antibodies in Myeloma: How They Work, Side Effects & CAR-T Comparison | Peter Forsberg MD
Personalized Vaccine for Smoldering Myeloma: Could It Prevent Progression? | IMS 2026
Second Cancers After Myeloma: Who Faces Higher Risk? | IMS 2026
How Is Myeloma Treatment Changing? Quadruplets, CAR-T, Bispecifics and New Therapies | IMS 2026
Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026
What Does MRD-Negative Mean in Multiple Myeloma? Testing, Maintenance & Treatment Decisions
Talquetamab Taste Changes in Multiple Myeloma: What Helps and What Doesn’t? -TALISMAN Study | #IMS26
Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26
Should You Use the Best Myeloma Treatments Early or Save Them for Relapse?